¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"phase shift effect"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • disperse phase
    ºÐ»ê±â
  • diurnal phase
    ÁÖ°£»ó
  • expiratory phase
    È£±â»ó
  • expiratory phase time
    ³¯¼û½Ã°£, È£±â½Ã°£
  • exponential phase
    Áö¼öÁõ½Ä±â
  • ejection phase
    ¹ÚÃâ±â
  • equilibrium phase
    ÆòÇü±â
  • erythrocytic phase
    ÀûÇ÷±¸³»¹ßÀ°±â
  • growth phase
    Áõ½Ä±â
  • intuitive phase
    Á÷°ü±â
  • involutional phase
    ÅðÈ­±â
  • isovolumic contraction phase
    µî¿ëÀû¼öÃà±â
  • implantational phase
    Âø»ó±â
  • inflow phase
    À¯ÀÔ±â
  • in-phase image
    À§»ó³»¿µ»ó
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • shielding effect
    Â÷ÆóÈ¿°ú, °¡¸²È¿°ú
  • shunt effect
    Áö¸§±æÈ¿°ú, ¼ÇƮȿ°ú
  • sialagogic effect
    ħºÐºñÃËÁøÈ¿°ú
  • side effect
    ºÎÀÛ¿ë
  • signal effect
    ½Åȣȿ°ú
  • somatic effect
    ½Åü¿µÇâ
  • stochastic effect
    È®·ü·ÐÀûÈ¿°ú
  • suction effect
    Èí¼öÈ¿°ú
  • summation effect
    °¡ÁßÈ¿°ú
  • synergistic effect
    »ó½ÂÈ¿°ú
  • teratogenic effect
    ±âÇüÀ¯¹ßÀÛ¿ë
  • toxic effect
    Áßµ¶È¿°ú, Áßµ¶ÀÛ¿ë
  • trapdoor effect
    ¶Ñ²±¹®È¿°ú
  • no-observed-effect level
    ¹«È¿°ú°üÂû¼öÁØ
  • 3D phase contrast angiography
    »ïÂ÷¿øÀ§»ó´ëÁ¶Ç÷°üÁ¶¿µ¼ú
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • inspiratory phase time
    Èí±â»ó½Ã°£.
  • phallic stage (phase)
    ³²±Ù±â(ÑûÐÆÑ¢).
  • phase
    »ó, ±â
  • phase
    ˤȗ
  • phase 1 study
    ÀÓ»óÁ¦1»ó½ÃÇè.
  • phase I block
    Á¦1»óÂ÷´Ü.
  • phase advance
    »óÀüÁø(ßÓîñòä)
  • phase angle
    À§»ó°¢(êÈßÓÊÇ).
  • phase angle
    À§»ó °¢
  • phase artifact
    À§»ó Àΰø¹°
  • phase axis
    ˤȗ ̈
  • phase boundary
    »ó°è(Ë×Ë­).
  • phase boundary force
    »ó°è(Àü)·Â(ßÓÍ£ ï³æ³).
  • phase boundary potential
    »ó°èÀüÀ§(ßÓÍ£ ï³êÈ).
  • phase coherence
    À§»ó °áÁý
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • effect concentration(=activity)
    À¯È¿³óµµ(êóüùÒØÓø)
  • effect, Pasteur
    ÆÄ½ºÆ©¸£È¿°ú
  • effect, cytopathogenic
    ¼¼Æ÷º´º¯È¿°ú
  • electrophonic effect
    Àü±âû°¢È¿°ú
  • entry slice effect
    À¯ÀÔ ´Ü¸é È¿°ú
  • extinction effect
    ¼Ò¸êÈ¿°ú(ÊÙÌ·Ë­).
  • extrapyramidal side effect
    Ãßü¿Ü·ÎºÎÀÛ¿ë(õÞô÷èâÖØÜùíÂéÄ)
  • fast scan effect
    °í¼Ó ½ºÄµ È¿°ú
  • first pass effect
    ÀÏÂ÷Åë°úÈ¿°ú.
  • glucose effect
    Æ÷µµ´çÈ¿°ú
  • gradient echo effect
    °æ»ç ¿¡ÄÚ È¿°ú
  • green house effect
    ¿Â½ÇÈ¿°ú
  • halo effect
    ´Þ¹«¸® È¿°ú
  • hearing, binaural (effect)
    ¾çÀÌû(È¿°ú)
  • heat effect
    ¿­È¿°ú
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • Raman effect
    ¶ó¸¸ È¿°ú(üùÍý)
  • relaxation effect
    ÀÌ¿Ï È¿°ú(ì¬èÐüùÍý)
  • secondary charge effect
    ÀÌÂ÷ ÇÏÀüÈ¿°ú(ì£ó­ùÃï³üùÍý)
  • secondary isotope effect
    ÀÌÂ÷ µ¿À§¿ø¼ÒÈ¿°ú(ì£ó­ÔÒêÈêªáÈüùÍý)
  • sparing effect
    ¿¹ºñÈ¿°ú(çãÝáüùÍý)
  • spreading position effect
    ÆÛÁü À§Ä¡ È¿°ú(êÈöÇüùÍý)
  • Stark effect
    ½ºÅ¸Å© È¿°ú(üùÍý)
  • thyrotoxic effect
    °©»ó¼±Áßµ¶ È¿°ú (Ë£ßÒàÍñéÔ¸üùÍý)
  • time factor effect
    ½Ã°£ÀÎÀÚ È¿°ú (ãÁÊàì×í­üùÍý)
  • trans effect
    Æ®¶õ½º È¿°ú(üùÍý)
  • Tyndall effect
    ƾ´Þ È¿°ú(üùÍý)
  • wall effect
    º®(Ûú)È¿°ú(üùÍý)
  • Warbug effect
    ¹Ù¸£ºÎ¸£Å© È¿°ú(üùÍý)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
ITE insufficient therapeutic effect; in the ear [hearing aid]; in-training examination; intrapulmonary i...
JFET junction field effect transistor
LEL lower explosive limit; lowest effect level
MOSFET metal oxide semiconductor field effect transistor
NE national emergency; necrotic enteritis; necrotizing enterocolitis; nephropathia epidemica; nerve end...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
PEV Position effect variegation
PAE Post Antibiotic Effect
PAFE Post-antifungal effect
PNEC Predicted No Effect Concentration
RERF Radiation Effect Research Foundation
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • harmful effect
    À§ÇØ ÀÛ¿ë
    À§ÇèÇÑ ÀçÇØ. Á¶Á÷À̳ª »ý¸íü¿¡ ÇØ·Î¿î ¿µÇâÀ» ³¢Ä¡´Â ÀÛ¿ë.
  • heel effect
    Èú È¿°ú
    ¾ç±Ø °æ»ç °¢µµ¿¡ µû¸¥ È¿°ú.
  • indirect effect
    °£Á¢ È¿°ú
  • isotopic effect
    µ¿À§ ¿ø¼Ò È¿°ú
  • lethal effect
    Ä¡»ç È¿°ú
  • longitudinal effect
    Á¾ È¿°ú, Á¾Àû È¿°ú
  • misregistration effect
    ¿Àµî·Ï È¿°ú
  • modulating effect
    Á¶Àý È¿°ú
  • muscle effect
    ±ÙÀ° È¿°ú
  • myocardium,aging effect
    ³ëÈ­ Çö»ó
  • Nagler effect
    ³ª±Û·¯ È¿°ú
  • nonallergic side effect
    ºñ¾Ë·¹¸£±â¼º ºÎÀÛ¿ë
  • oral effect of medication
    Åõ¾àÀÇ ±¸°­³» È¿°ú
  • overkill effect
    °úÀ× Ä¡»ç È¿°ú
  • pain-inhibiting effect
    µ¿Åë ¹æÇØ È¿°ú
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
zygotic effect gene <genetics> A gene whose phenotype is dependent on the genotype of the zygote, rather than the genotype of the mother.
See: maternal effect gene.
(18 Nov 1997)
late effect Side effects of chemotherapy and/or radiotherapy which only become apparent with long-term monitoring of the patient over a period of years. These are of particular concern in patients below the age of puberty.
(18 Nov 1997)
founder effect The establishment of a new population by a few original founders (in an extreme case, by a single fertilized female) which carry only a small fraction of the total genetic variation of the parental population [Ernst Mayr, 1963]. The result is that a given allele, gene, chromosome, or part of a chromosome found in members of the population can be traced back to one ancestral individual.
(09 Oct 1997)
accelerated phase of leukaemia Refers to chronic myelogenous leukaemia that is progressing. The number of immature, abnormal white blood cells in the bone marrow and blood is higher than in the chronic phase, but not as high as in the blast phase.
(12 Dec 1998)
acceleration phase <cell biology, cell culture> A period of increasing growth before the log phase in a culture of microbes.
After the culture is started on a medium, at first there is no growth (the lag phase) and then the microbes start to gradually grow (acceleration phase) until they reach a constant maximum rate of growth (log phase).
(15 Jan 1998)
acute-phase protein <haematology> These plasma proteins (in addition to fibrinogen) increase 25% or more in response to inflammation and injury are under direct control of interleukin-6 (IL-6) (hepatocyte-stimulating factor).
Other proteins which increase are ceruloplasmin, C3 and C4 which increase 50% or more; alpha-1 acid glycoprotein, alpha-1 antitrypsin, haptoglobin and fibrinogen (the major determinant of viscosity 1 ) which increase two- to fourfold; C-reactive protein (CRP) and serum amyloid A which increase several hundred-fold.
Despite long-held clinical opinion to the contrary, available data indicate that neither ESR nor measurement of specific acute-phase reactants are useful in excluding underlying infection or inflammation regardless of the pretest probability.
These proteins are secreted into the blood in increased or decreased quantities by hepatocytes in response to trauma, inflammation, or disease. They can serve as inhibitors or mediators of the inflammatory processes. Certain acute-phase proteins have been used to diagnose and follow the course of diseases or as tumour markers.
See also: amyloid, c-reactive protein, erythrocyte sedimentation rate, viscosity.
(25 Jun 1999)
acute-phase reaction <immunology, rheumatology> Refers to the changes in synthesis of certain proteins within the serum during an inflammatory response, which provides rapid protection for the host against microorganisms via non-specific defense mechanisms.
It consists of fever, an increase in inflammatory humoral factors, and an increased synthesis by hepatocytes of a number of proteins or glycoproteins usually found in the plasma; the reaction is mediated by endogenous pyrogens, the hypothalamus, adrenal hormones, and other factors.
(12 Jul 2000)
anal phase In psychoanalytic personality theory, the stage of psychosexual development, occurring when a child is between 1 and 3 years, during which activities, interests, and concerns are centreed around the anal zone.
(05 Mar 2000)
aqueous phase The water portion of a system consisting of two liquid phase's, one mainly water, the other a liquid immiscible with water (e.g., benzene, ether).
(05 Mar 2000)
blast phase Refers to advanced chronic myelogenous leukaemia. In this phase, the number of immature, abnormal white blood cells in the bone marrow and blood is extremely high. Also called blast crisis.
(12 Dec 1998)
g0 phase Phase of the cell cycle where cells exist in a quiescent state. These cells have unduplicated DNA, degraded RNA and protein, and low enzyme activity. The ability to switch between g0 and g1 (and vice versa) determines the post-embryonic cell proliferation rate and is defectively controlled in neoplastic cells.
(12 Dec 1998)
g1 phase <cell biology, molecular biology> The period during interphase in the cell cycle between mitosis and the S phase (when DNA is replicated).
Also known as the decision period of the cell, because the cell decides to divide when it enters the s phase. The G stands for gap.
(09 Oct 1997)
g2 phase <cell biology, molecular biology> The period during interphase in the cell cycle between the S phase (when DNA is replicated) and mitosis (when the nucleus, then cell, divides).
at this time, the cell checks the accuracy of DNA replication and prepares for mitosis. The G stands for gap.
(09 Oct 1997)
radial growth phase The early pattern of growth of cutaneous malignant melanoma, in which tumour cells spread laterally in the epidermis.
(05 Mar 2000)
Gap1 phase The period of the cell cycle after cell division when there is synthesis of RNA and protein; it may last for a few hours in rapidly growing tissue or a lifetime in non-renewing cells such as nerve cells.
Synonym: Gap1 phase, postmitotic phase.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á